glp-1 receptor agonists effects on cardiovascular risk reduction for the of Atherosclerotic in Patients With Type 2 Diabetes GLP-1 Receptor Agonists in the

Future studies should also explore the potential of emerging therapies, such as dual and triple agonists (e.g., tirzepatide and retatrutide), which have shown even greater efficacy in weight loss [20, 21]

Both acute GLP-1 infusion (65, 66) and a single liraglutide dose (67) decreased plasma ANG II concentration in healthy subjects and type 2 diabetic patients, consistently with an inhibitory effect of GLP-1 on renin secretion (68, 69)

[DOI] [PubMed] [Google Scholar] 2.Lanaspa M.A., Sanchez-Lozada L.G., Choi Y.J., Cicerchi C., Kanbay M., Roncal-Jimenez C.A., Ishimoto T., Li N., Marek G., Duranay M., et al

Will small molecule oral GLP-1 receptor agonists eventually replace injectable GLP-1 receptor agonists

Recognizing the importance of leading medications like Zepbound, Semaglutide GLP-1 (Ozempic), and Wegovy, we incorporate these FDA-approved treatments into our strategies for managing chronic health issues such as obesity